Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd

Link copied
Case Copied 36 min read

FEDERAL COURT OF AUSTRALIA

Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd [2019] FCAFC 28

Appeal from: Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd
(No 3)
[2018] FCA 2060
File number: NSD 2398 of 2018
Judges: JAGOT, YATES AND MOSHINSKY JJ
Date of judgment: 22 February 2019
Catchwords:

[PRACTICE AND PROCEDURE- patents – interlocutory injunction application – prima facie case
– validity of patents – novelty – balance of convenience

- leave to appeal dismissed.

Cases cited:

GenRx Pty Ltd v Sanofi-Aventis [2007] FCA 148

House v The King (1936) 55 CLR 499

Interpharma Pty Ltd v Commissioner of Patents [[2008] FCA 1498

Janssen Sciences Ireland UC v Alphapharm Pty Ltd [2017] FCA 1399

Love v Thwaites & Anor (No 4) [2012] VSC 521

Love v Thwaites & Anor [2014] VSCA 56

Samsung Electronics Company Ltd v Apple Inc (2011) 217 FCR 238

Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (No 3) [2018] FCA 2060

Warner-Lambert Co LLC v Apotex Pty Ltd [2014] FCAFC 59

Date of hearing: 8 February 2019
Registry: New South Wales
Division: General
National Practice Area: Intellectual Property
Sub-area: Patents and Associated Statutes
Category: Catchwords
Number of paragraphs: 54
Counsel for the Applicants: C Dimitriadis SC with A R Lang
Solicitor for Applicants: Jones Day
Counsel for the Respondent: T D Cordiner QC with J S Cooke
Solicitor for the Respondent: MinterEllison

ORDERS

NSD 2398 of 2018
BETWEEN:

SANOFI- AVENTIS DEUTSCHLAND GMBH & ANOR
Applicants

AND:

ALPHAPHARM PTY LTD
Respondent

JUDGES:

JAGOT, YATES AND MOSHINSKY JJ

DATE OF ORDER:

22 FEBURARY 2019

THE COURT ORDERS THAT:

1.The application for leave to appeal be dismissed.

2.The applicants pay the respondent’s costs of the application as agreed or taxed.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

THE COURT:

  1. This application for leave to appeal concerns the primary judge’s refusal to grant the applicants, Sanofi-Aventis Deutschland GmbH and Sanofi-Aventis Australia Ltd (together, Sanofi), an interlocutory injunction to restrain the respondent, Alphapharm Pty Ltd, from launching its SEMGLEE insulin glargine (rDNA) solution for injection injector pen, referred to as the Semglee product: Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (No 3) [2018] FCA 2060.

  2. Sanofi contends that the primary judge’s refusal to grant the interlocutory injunction is attended by sufficient doubt to justify the Full Court reconsidering the matter and that, assuming the primary judge’s decision to be wrong, it would suffer substantial injustice.  The latter condition of substantial injustice if the decision is wrong is satisfied and, as a result, it was decided that the application for leave to appeal and the appeal should be heard together.

  3. We consider that the application for leave to appeal should be refused.  The primary judge’s decision is not attended by sufficient doubt to justify the Full Court reconsidering the application for an interlocutory injunction.

  4. The draft notice of appeal identifies 11 alleged errors, many containing multiple aspects each said to constitute error. 

  5. One answer to the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2019] FCAFC 28
Decision Date

CaseChat Overview and Summary

Sanofi-Aventis Deutschland GmbH sought to appeal against a decision of the Federal Court of Australia that dismissed their application for an interlocutory injunction against Alphapharm Pty Ltd. The primary issue was whether certain pharmaceutical patents held by Sanofi-Aventis were valid and if Alphapharm had infringed them by manufacturing and selling generic versions of the patented drugs. A critical aspect of the case was the determination of whether Sanofi-Aventis had established a prima facie case for patent infringement and if the balance of convenience favoured granting an interlocutory injunction.

The court was required to determine the validity of Sanofi-Aventis’s patents, specifically whether they were novel and non-obvious, and whether Alphapharm had infringed these patents. Additionally, the court had to consider the balance of convenience to decide if an interlocutory injunction should be granted. The court examined the evidence presented regarding the novelty of the patents and the infringement by Alphapharm, weighing the potential harm to both parties if the injunction was or was not granted.

Sanofi-Aventis argued that their patents were valid and that Alphapharm had infringed them by producing generic versions of the drugs. However, the court found that Sanofi-Aventis had not demonstrated a prima facie case for patent validity or infringement. The court also concluded that the balance of convenience did not favour granting an interlocutory injunction. Consequently, the application for leave to appeal was dismissed. The applicants were ordered to pay the respondent’s costs of the application as agreed or taxed.

Orders

Orders of the court

1. The application for leave to appeal be dismissed.

2. The applicants pay the respondent’s costs of the application as agreed or taxed.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established